HomeCompareBVNKF vs VICI

BVNKF vs VICI: Dividend Comparison 2026

BVNKF yields 6.73% · VICI yields 6.52%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VICI wins by $935.0K in total portfolio value· pulled ahead in Year 2
10 years
BVNKF
BVNKF
● Live price
6.73%
Share price
$29.71
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.2K
Annual income
$1,032.71
Full BVNKF calculator →
VICI
VICI Properties Inc.
● Live price
6.52%
Share price
$27.32
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$966.2K
Annual income
$607,376.13
Full VICI calculator →

Portfolio growth — BVNKF vs VICI

📍 VICI pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBVNKFVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BVNKF + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BVNKF pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BVNKF
Annual income on $10K today (after 15% tax)
$572.20/yr
After 10yr DRIP, annual income (after tax)
$877.80/yr
VICI
Annual income on $10K today (after 15% tax)
$554.58/yr
After 10yr DRIP, annual income (after tax)
$516,269.71/yr
At 15% tax rate, VICI beats the other by $515,391.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BVNKF + VICI for your $10,000?

BVNKF: 50%VICI: 50%
100% VICI50/50100% BVNKF
Portfolio after 10yr
$498.7K
Annual income
$304,204.42/yr
Blended yield
61.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

BVNKF
No analyst data
Altman Z
6.8
Piotroski
8/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+15.7% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BVNKF buys
0
VICI buys
0
No recent congressional trades found for BVNKF or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBVNKFVICI
Forward yield6.73%6.52%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$31.2K$966.2K
Annual income after 10y$1,032.71$607,376.13
Total dividends collected$8.6K$926.2K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: BVNKF vs VICI ($10,000, DRIP)

YearBVNKF PortfolioBVNKF Income/yrVICI PortfolioVICI Income/yrGap
1$11,373$673.17$11,361$941.49+$12.00BVNKF
2← crossover$12,885$715.53$13,320$1,481.32$435.00VICI
3$14,544$757.60$16,284$2,405.01$1.7KVICI
4$16,362$799.23$21,040$4,071.78$4.7KVICI
5$18,347$840.27$29,209$7,285.49$10.9KVICI
6$20,512$880.60$44,443$14,006.51$23.9KVICI
7$22,868$920.10$75,822$29,512.55$53.0KVICI
8$25,428$958.68$148,733$69,726.75$123.3KVICI
9$28,204$996.24$344,394$189,413.75$316.2KVICI
10$31,211$1,032.71$966,234$607,376.13$935.0KVICI

BVNKF vs VICI: Complete Analysis 2026

BVNKFStock

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Full BVNKF Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this BVNKF vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BVNKF vs SCHDBVNKF vs JEPIBVNKF vs OBVNKF vs KOBVNKF vs MAINBVNKF vs NNNBVNKF vs EPRTBVNKF vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.